Chemours Co (CC) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-05

Key Insights

Chemours released Q1 2026 financial results on May 5, 2026, with an earnings call scheduled for May 6, 2026, indicating ongoing investor communication about quarterly performance.
The company is providing an investor presentation alongside earnings results, suggesting management is prepared to discuss strategic initiatives and financial outlook with stakeholders.
This is a routine quarterly earnings disclosure filed under Item 2.02, with no indication of material events, guidance changes, or significant business developments that would materially impact the stock.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-30

All 11 director nominees were elected with strong shareholder support, with voting percentages ranging from 95.8% to 99.3%, indicating solid confidence in board leadership and governance.
The 2026 Equity and Incentive Plan was approved with 108.8 million votes in favor but faced meaningful opposition with 3.7 million votes against, suggesting some shareholder concerns about compensation or equity dilution.
The advisory say-on-pay vote passed overwhelmingly with 110.1 million votes for and only 2.5 million against, demonstrating strong shareholder approval of executive compensation practices.
PricewaterhouseCoopers LLP was ratified as independent auditor with 128.3 million votes in favor and minimal opposition (813,925 against), showing stable audit relationship and shareholder confidence in financial oversight.

Filed: 2026-03-12

Chemours completed the private offering of $700 million in 7.875% Senior Notes due 2034, which will be used to fund the redemption of existing senior notes and provide additional liquidity.
The Notes have customary terms and conditions, including a make-whole provision for early redemption and a change-of-control put option, which provide flexibility to the company.
The proceeds from the Notes offering will help Chemours optimize its capital structure and reduce interest expense going forward.

Filed: 2026-02-26

Chemours is raising $700 million in senior unsecured notes due in 2034, an increase from the previously announced $600 million offering.
The notes will carry a 7.875% interest rate, indicating the company is likely seeking capital for expansion or refinancing purposes.
The timing of the debt offering, in the midst of current market conditions, suggests Chemours sees favorable opportunities for growth or improved financing terms.

Filed: 2026-02-19

Chemours reported strong Q4 2025 and full year 2025 financial results, indicating the company's business performance continues to be robust.
The company plans to hold an investor presentation on February 20, 2026, providing an opportunity for investors to gain further insights into the company's operations and strategic direction.
Chemours' stock ticker symbol (CC) and its listing on the New York Stock Exchange suggest the company's securities are publicly traded and actively monitored by investors.

Filed: 2026-01-16

Chemours is selling 10 parcels of land in Taiwan for approximately $360 million, which will be used to reduce the company's debt obligations.
The sale is expected to be completed through one or more closings by mid-year 2026, subject to certain closing conditions and local regulatory approval.
The transaction was negotiated on an arms-length basis with four affiliated entities, indicating it was a strategic decision rather than a related-party transaction.

Other reports for Chemours Co

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.